Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siwu Tang is a classic Traditional Chinese Medicine (TCM) formulation composed of four primary herbs: *Rehmannia glutinosa* (prepared), *Angelica sinensis*, *Paeonia lactiflora*, and *Ligusticum chuanxiong*. Traditionally used to tonify blood and regulate menstruation, it is being investigated by researchers at Singapore General Hospital for its potential anti-thrombotic and "blood-activating" properties. The formulation is hypothesized to influence platelet function and the coagulation profile, potentially increasing bleeding tendency. Clinical research, including a randomized, double-blind, placebo-controlled crossover study (NCT00162110), has evaluated its effects on healthy volunteers both as a standalone treatment and in combination with anti-platelet agents like aspirin. The active phytochemicals within the formula, such as ferulic acid and ligustrazine, are believed to contribute to its ability to inhibit platelet aggregation and modulate clotting factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Siwu Tang.